Exosome-derived miRNAs and ovarian carcinoma progression von Vaksman, Olga, Tropé, Claes, Davidson, Ben, Reich, Reuven

Volltext

Ezrin Is Associated with Disease Progression in Ovarian Carcinoma von Horwitz, Vered, Davidson, Ben, Stern, Dganit, Tropé, Claes G, Tavor Re'em, Tali, Reich, Reuven

Volltext

The clinical and diagnostic role of microRNAs in ovarian carcinoma von Davidson, Ben, Tropé, Claes G, Reich, Reuven

Volltext

Long-Term Outcomes After Pelvic Radiation for Early-Stage Endometrial Cancer von ONSRUD, Mathias, CVANCAROVA, Milada, HELLEBUST, Taran P, TROPE, Claes G, KRISTENSEN, Gunnar B, LINDEMANN, Kristina

Volltext

Diagnosis and treatment of sarcoma of the uterus. A review von Tropé, Claes G., Abeler, Vera M., Kristensen, Gunnar B.

Volltext

MicroRNAs in Ovarian Cancer von Katz, Betina, MD, PhD, Tropé, Claes G., MD, PhD, Reich, Reuven, PhD, Davidson, Ben, MD, PhD

Volltext

Ovarian cancer: diagnostic, biological and prognostic aspects von Davidson, Ben, Tropé, Claes G

Volltext

Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Int... von Makar, Amin P., Tropé, Claes G., Tummers, Philippe, Denys, Hannelore, Vandecasteele, Katrien

Volltext

The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas von Agostini, Antonio, Brunetti, Marta, Davidson, Ben, Tropé, Claes G., Eriksson, Ane Gerda Z., Heim, Sverre, Panagopoulos, Ioannis, Micci, Francesca

Volltext

Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions von Slipicevic, Ana, Holth, Arild, Hellesylt, Ellen, Tropé, Claes G, Davidson, Ben, Flørenes, Vivi Ann

Volltext

CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma von Nymoen, Dag Andre, Holth, Arild, Hetland Falkenthal, Thea E, Tropé, Claes G, Davidson, Ben

Volltext

Expression and clinical role of long non-coding RNA in high-grade serous carcinoma von Filippov-Levy, Natalie, Cohen-Schussheim, Hallel, Tropé, Claes G., Hetland Falkenthal, Thea E., Smith, Yoav, Davidson, Ben, Reich, Reuven

Volltext

TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma von Broner, Esther Channah, MSc, Tropé, Claes G., MD, PhD, Reich, Reuven, PhD, Davidson, Ben, MD, PhD

Volltext

DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets von Wu, Qinghua, Lothe, Ragnhild A, Ahlquist, Terje, Silins, Ilvars, Tropé, Claes G, Micci, Francesca, Nesland, Jahn M, Suo, Zhenhe, Lind, Guro E

Volltext

A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection von Tian, Wen-Juan, Chi, Dennis S., Sehouli, Jalid, Tropé, Claes G., Jiang, Rong, Ayhan, Ali, Cormio, Gennaro, Xing, Yan, Breitbach, Georg-Peter, Braicu, Elena Ioana, Rabbitt, Catherine A., Oksefjell, Halldis, Fotopoulou, Christina, Meerpohl, Hans-Gerd, du Bois, Andreas, Berek, Jonathan S., Zang, Rong-Yu, Harter, Philipp

Volltext

The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions von Davidson, Ben, MD PhD, Holth, Arild, BSc, Hellesylt, Ellen, MSc, Tan, Tuan Zea, PhD, Huang, Ruby Yun-Ju, MD PhD, Tropé, Claes, MD PhD, Nesland, Jahn M., MD PhD, Thiery, Jean Paul, PhD

Volltext

HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival von Davidson, Ben, MD, PhD, Holth, Arild, BSc, Hellesylt, Ellen, MSc, Hadar, Rivka, MSc, Katz, Betina, MD, PhD, Tropé, Claes G., MD, PhD, Reich, Reuven, PhD

Volltext

Adjuvant Chemotherapy for Early-Stage Ovarian Cancer: Review of the Literature von Tropé, Claes, Kaern, Janne

Volltext

Epithelial–mesenchymal transition markers in malignant ovarian germ cell tumors von Solheim, Olesya, Førsund, Mette, Tropé, Claes G., Kraggerud, Sigrid Marie, Nesland, Jahn M., Davidson, Ben

Volltext

Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV? von Tropé, Claes G, Elstrand, Mari B, Sandstad, Berit, Davidson, Ben, Oksefjell, Halldis

Volltext